Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Harvard Business School
Dow
Mallinckrodt
Johnson and Johnson

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Litigation Details for Novartis Pharmaceuticals Corporation v. Watson Laboratories Inc. (D. Del. 2011)

See Plans and Pricing

« Back to Dashboard

Novartis Pharmaceuticals Corporation v. Watson Laboratories Inc. (D. Del. 2011)

Docket   Start Trial Date Filed 2011-11-09
Court District Court, D. Delaware Date Terminated 2014-08-04
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Parties LTS LOHMANN THERAPIE-SYSTEME AG; NOVARTIS AG; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.; NOVARTIS PHARMA AG; NOVARTIS PHARMACEUTICALS CORPORATION; WATSON LABORATORIES INC.; WATSON PHARMA INC.; WATSON PHARMACEUTICALS INC.
Patents 5,602,176; 6,316,023
Attorneys Daniel M. Silver; Erika R. Caesar; Melanie K. Sharp; Michael P. Kelly
Link to Docket External link to docket
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Watson Laboratories Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Novartis Pharmaceuticals Corporation v. Watson Laboratories Inc. (D. Del. 2011)

Date Filed Document No. Description Snippet Link To Document
2011-11-09 1 United States Letters Patent No. 5,602,176 (“the ’176 patent”). The ’176 patent was duly and legally …United States Letters Patent No. 6,316,023 (“the ’023 patent”). The ’023 patent was duly and legally issued…United States Letters Patent No. 6,335,031 (“the ’031 patent”). The ’031 patent was duly and legally issued…the ’031 patent is attached hereto as Exhibit C. 38. The ’023 and ’031 patents were initially…the ’176, ’023, and ’031 patents was an act of infringement of these patents. External link to document
2011-11-09 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,602,176; 6,316,023 B1; 6,335,031…2011 4 August 2014 1:11-cv-01112 830 Patent None District Court, D. Delaware External link to document
2014-08-05 46 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,602,176; 6,316,023 B1; 6,335,031…2011 4 August 2014 1:11-cv-01112 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Dow
Colorcon
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.